tradingkey.logo
tradingkey.logo
Suchen

PharmaCyte Biotech Inc

PMCB
Zur Watchlist hinzufügen
0.804USD
-0.146-15.38%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
8.64MMarktkapitalisierung
VerlustKGV TTM

PharmaCyte Biotech Inc

0.804
-0.146-15.38%

mehr Informationen über PharmaCyte Biotech Inc Unternehmen

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

PharmaCyte Biotech Inc Informationen

BörsenkürzelPMCB
Name des UnternehmensPharmaCyte Biotech Inc
IPO-datumSep 11, 2003
CEOSilverman (Joshua N)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 11
Addresse3960 Howard Hughes Parkway, Suite 500
StadtLAS VEGAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl89169
Telefon19175952850
Websitehttps://pharmacyte.com/
BörsenkürzelPMCB
IPO-datumSep 11, 2003
CEOSilverman (Joshua N)

Führungskräfte von PharmaCyte Biotech Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Silverman (Joshua)
3.41%
Citadel Advisors LLC
2.14%
HRT Financial LP
1.70%
Schechter (Jonathan L)
1.23%
Geode Capital Management, L.L.C.
1.15%
Andere
90.36%
Aktionäre
Aktionäre
Anteil
Silverman (Joshua)
3.41%
Citadel Advisors LLC
2.14%
HRT Financial LP
1.70%
Schechter (Jonathan L)
1.23%
Geode Capital Management, L.L.C.
1.15%
Andere
90.36%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
5.74%
Hedge Fund
3.53%
Investment Advisor
2.86%
Investment Advisor/Hedge Fund
2.42%
Research Firm
0.35%
Venture Capital
0.23%
Andere
84.87%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
67
1.07M
9.99%
+347.99K
2025Q4
60
434.85K
4.29%
-381.18K
2025Q3
61
457.38K
6.73%
-604.80K
2025Q2
66
1.28M
18.72%
-522.91K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Silverman (Joshua)
366.25K
3.41%
-100.00K
-21.45%
Feb 01, 2026
Citadel Advisors LLC
229.72K
2.14%
+215.19K
+1480.91%
Dec 31, 2025
HRT Financial LP
182.80K
1.7%
+182.80K
--
Dec 31, 2025
Schechter (Jonathan L)
132.50K
1.23%
-60.00K
-31.17%
Feb 01, 2026
Geode Capital Management, L.L.C.
123.84K
1.15%
-2.76K
-2.18%
Dec 31, 2025
Sabby Management, LLC
100.00K
0.93%
+100.00K
--
Dec 31, 2025
Renaissance Technologies LLC
94.04K
0.88%
+14.04K
+17.54%
Dec 31, 2025
Weinstein (Robert)
41.25K
0.38%
--
--
Feb 01, 2026
Northern Trust Investments, Inc.
35.60K
0.33%
+16.39K
+85.34%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI